Histone deacetylase inhibitor uses p21Cip1 to maintain anergy in CD4+ T cells

International Immunopharmacology

Volumn 9, Issue 11, 2009, Pages 1289-1297

  Dagtas, A Selma ^a   Edens, R Erik ^a   Gilbert, Kathleen M ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Cell proliferation; T cells; Tolerance suppression anergy; Transgenic knockout mice

Indexed keywords

6 (1,3 DIOXO 1H,3H BENZO[DE]ISOQUINOLIN 2 YL) N HYDROXYHEXANAMIDE; ANTIGEN; BUTYRIC ACID; CYCLIN DEPENDENT KINASE INHIBITOR 1; HISTONE DEACETYLASE INHIBITOR; OKADAIC ACID; TRICHOSTATIN A;

ACETYLATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN SPECIFICITY; ARTICLE; CD4+ T LYMPHOCYTE; CELL PROLIFERATION; CLONAL ANERGY; CONTROLLED STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; TH1 CELL; UPREGULATION;

ACETYLATION; ANIMALS; BUTYRATES; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CLONAL ANERGY; CYCLIN-DEPENDENT KINASE INHIBITOR P21; ENZYME INDUCTION; HISTONE DEACETYLASE INHIBITORS; HYDROXAMIC ACIDS; HYDROXYLAMINES; MICE; MICE, INBRED C57BL; OKADAIC ACID; QUINOLINES; TH1 CELLS;

EID: 70249144329     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2009.07.012     Document Type: Article

References (39)

1. Kruh J., Defer N., and Tichonicky L. Molecular and cellular action of butyrate. CR Seances Soc Biol Fil 186 (1992) 12-25
2. Gilbert K.M., and Weigle W.O. Th1 cell anergy and blockade in G1a phase of the cell cycle. J Immunol 151 (1993) 1245-1254
3. Gilbert K.M., Fecher N., Wahid R., and Fifer E.K. Potential clinical use of butyric acid derivatives to induce antigen-specific T cell inactivation. J Pharacol Exp Ther 294 (2000) 1146-1153
4. Jackson S.K., DeLoose A., and Gilbert K.M. Induction of anergy in Th1 cells is associated with increased levels of cyclin-dependent kinase inhibitors P21cip1 and P27kip1. J Immunol 166 (2001) 952-958
5. Marks P.A., Richon V.M., Breslow R., and Rifkind R.A. Histone deacetylase inhibitors as new cancer drugs. Curr Opin Oncol 13 6 (2001) 477-483
6. Edens R.E., Dagtas S., and Gilbert K.M. Histone deacetylase inhibitors induce antigen specific anergy in lymphocytes: a comparative study. Int Immunopharmacol 6 11 (2006) 1673-1681
7. Mariadason J.M., Corner G.A., and Augenlicht L.H. Genetic reprogramming in pathways of colonic cell maturation induced by short chain fatty acids: comparison with trichostatin A, sulindac, and curcumin and implications for chemoprevention of colon cancer. Cancer Res 60 16 (15-8-2000) 4561-4572
8. Van Lint C., Emiliani S., and Verdin E. The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Expr 5 4-5 (1996) 245-253
9. Chen Y.X., Fang J.Y., Zhu H.Y., Lu R., Cheng Z.H., and Qiu D.K. Histone acetylation regulates P21(WAF1) expression in human colon cancer cell lines. World J Gastroenterol 10 18 (15-9-2004) 2643-2646
10. Catalano M.G., Fortunati N., Pugliese M., Costantino L., Poli R., Bosco O., et al. Valproic acid induces apoptosis and cell cycle arrest in poorly differentiated thyroid cancer cells. J Clin Endocrinol Metab 90 3 (2005) 1383-1389
11. Richon V.M., Sandhoff T.W., Rifkind R.A., and Marks P.A. Histone deacetylase inhibitor selectively induces P21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci U S A 97 18 (29-8-2000) 10014-10019
12. Harper J.W., Elledge S.J., and Keyomarsi K. Inhibition of cyclin-dependent kinase by P21. Mol Biol Cell 6 (1995) 387-400
13. Li R., Waga S., Hannon G.J., Beach D., and Stillman B. Differential effects by the P21 CDK inhibitor on PCNA-dependent DNA replication and repair. Nature 371 (1994) 534-537
14. Xue Y., Ramaswamy N.T., Hong X., and Pelling J.C. Association of JNK1 with P21waf1 and P53: modulation of JNK1 activity. Mol Carcinog 36 (2003) 38-44
15. Jackson S.K., DeLoose A., and Gilbert K.M. The ability of antigen, but not IL-2, to promote N-butyrate-induced Th1 cell anergy is associated with increased expression and altered association patterns of cyclin dependent kinase inhibitors. Immunology 106 (2002) 486-495
16. Chen D., Heath V., O'Garra A., Johnston J., and McMahon M. Sustained activation of the Raf-MEK-ERK pathway elicits cytokine unresponsiveness in T cells. J Immunol 163 (1999) 5796-5805
17. Boussiotis V.A., Freeman G.J., Taylor P.A., Berezovskaya A., Grass I., Blazar B.R., et al. P27kip1 functions as an anergy factor inhibiting interleukin 2 transcription and clonal expansion of alloreactive human and mouse helper T lymphocytes. Nat Med 6 (2000) 290-296
18. Powell J.D., Bruniquel D., and Schwartz R.H. TCR engagement in the absence of cell cycle progression leads to T cell anergy independent of P27(Kip1). Eur J Immunol 31 (2001) 3737-3746
19. Li L., Iwamoto Y., Berezovskaya A., and Boussiotis V.A. A pathway regulated by cell cycle inhibitor P27Kip1 and checkpoint inhibitor Smad3 is involved in the induction of T cell tolerance. Nat Immunol 7 11 (2006) 1157-1165
20. Gilbert K.M., Hoang K.D., and Weigle W.O. Th1 and Th2 clones differ in their response to a tolerogenic signal. J Immunol 144 (1990) 2063-2071
21. Biggs J.R., Kudlow J.E., and Kraft A.S. The role of the transcription factor Sp1 in regulating the expression of the WAF1/CIP1 gene in U937 leukemic cells. J Biol Chem 271 2 (12-1-1996) 901-906
22. Cohen P., Holmes C.F., and Tsukitani Y. Okadaic acid: a new probe for the study of cellular regulation. Trends Biochem Sci 15 3 (1990) 98-102
23. Wang Y.F., Chen N.S., Chung Y.P., Chang L.H., Chiou Y.H., and Chen C.Y. Sodium butyrate induces apoptosis and cell cycle arrest in primary effusion lymphoma cells independently of oxidative stress and P21(CIP1/WAF1) induction. Mol Cell Biochem 285 1-2 (2006) 51-59
24. Chopin V., Toillon R.A., Jouy N., Le, and Bourhis X. P21(WAF1/CIP1) is dispensable for G1 arrest, but indispensable for apoptosis induced by sodium butyrate in MCF-7 breast cancer cells. Oncogene 23 1 (8-1-2004) 21-29
25. Chen X., Wang J., Woltring D., Gerondakis S., and Shannon M.F. Histone dynamics on the interleukin-2 gene in response to T-cell activation. Mol Cell Biol 25 8 (2005) 3209-3219
26. Balomenos D., Martin-Caballero J., Garcia M.I., Prieto I., Flores J.M., Serrano M., et al. The cell cycle inhibitor P21 controls T cell proliferation and sex-linked lupus development. Nature Med 6 (2000) 171-176
27. Arias C.F., Ballesteros-Tato A., Garcia M.I., Martin-Caballero J., Flores J.M., Martinez A., et al. P21CIP1/WAF1 controls proliferation of activated/memory T cells and affects homeostasis and memory T cell responses. J Immunol 178 4 (15-2-2007) 2296-2306
28. Santiago-Raber M.L., Lawson B.R., Dummer W., Barnhouse M., Koundouris S., Wilson C.B., et al. Role of cyclin kinase inhibitor P21 in systemic autoimmunity. J Immunol 167 (2001) 4067-4074
29. Nasu K., Kohsaka H., Nonomura Y., Terada Y., Ito H., Hirokawa K., et al. Adenoviral transfer of cyclin-dependent kinase inhibitor genes suppresses collagen-induced arthritis in mice. J Immunol 165 12 (15-12-2000) 7246-7252
30. Nonomura Y., Kohsaka H., Nasu K., Terada Y., Ikeda M., and Miyasaka N. Suppression of arthritis by forced expression of cyclin-dependent kinase inhibitor P21(Cip1) gene into the joints. Int Immunol 13 6 (2001) 723-731
31. Goulvestre C., Chereau C., Nicco C., Mouthon L., Weill B., and Batteux F. A mimic of P21WAF1/CIP1 ameliorates murine lupus. J Immunol 175 10 (15-11-2005) 6959-6967
32. Garcia B.A., Busby S.A., Shabanowitz J., Hunt D.F., and Mishra N. Resetting the epigenetic histone code in the MRL-Lpr/Lpr mouse model of lupus by histone deacetylase inhibition. J Proteome Res 4 6 (2005) 2032-2042
33. Camelo S., Iglesias A.H., Hwang D., Due B., Ryu H., Smith K., et al. Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis. J Neuroimmunol 164 1-2 (2005) 10-21
34. Chung Y.L., Lee M.Y., Wang A.J., and Yao L.F. A therapeutic strategy uses histone deacetylase inhibitors to modulate the expression of genes involved in the pathogenesis of rheumatoid arthritis. Mol Ther 8 5 (2003) 707-717
35. Reilly C.M., Mishra N., Miller J.M., Joshi D., Ruiz P., Richon M., et al. Modulation of renal disease in MRL/Lpr mice by suberoylanilide hydroxamic acid. J Immunol 173 6 (15-9-2004) 4171-4178
36. Reddy P., Maeda Y., Hotary K., Liu C., Reznikov L.L., Dinarello C.A., et al. Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect. Proc Natl Acad Sci U S A 101 11 (16-3-2004) 3921-3926
37. Reddy P., Sun Y., Toubai T., Duran-Struuck R., Clouthier S.G., Weisiger E., et al. Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase-dependent DC functions and regulates experimental graft-versus-host disease in mice. J Clin Invest 118 7 (2008) 2562-2573
38. Tao R., de Zoeten E.F., Ozkaynak E., Chen C., Wang L., Porrett P.M., et al. Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat Med 13 11 (2007) 1299-1307
39. Tao R., de Zoeten E.F., Ozkaynak E., Wang L., Li B., Greene M.I., et al. Histone deacetylase inhibitors and transplantation. Curr Opin Immunol 19 5 (2007) 589-595